Subject: Varicose Vein Interventions (Lower Extremities)*

Effective Date: July 31, 2007

Department(s): Utilization Management

Policy: Interventional treatment of symptomatic lower extremity varicose veins is reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to delineate criteria of medical necessity of several types of treatment for varicose veins of the lower extremities.

Procedure:

1. Interventional treatment of varicose veins (ICD-9 454.0 – 454.8; 459.81; ICD-10 I83.001-I83.005, I83.008, I83.009, I83.011-I83.015, I83.015, I83.018, I83.019, I83.021-I83.025, I83.028, I83.029, I83.10-I83.12, I83.201- I83.205, I83.208, I83.209, I83.211- I83.215, I83.218, I83.219, I83.221- I83.225, I83.228, I83.229, I83.811-I83.813, I83.819, I83.891-I83.893, I83.899) is reimbursable if at least one of the following circumstances is present:

   A. Incompetence or reflux, and absence of deep venous occlusive disease, and vessel size \( \geq 3 \) mm, documented by Doppler and/or duplex ultrasonography

   OR

   Documented varicose tributaries, accessory or perforator veins in the absence of (or
successful prior treatment of) reflux in the saphenofemoral or saphenopopliteal junctions

AND

i. Failure of conservative management (including but not limited to leg elevation, compression hose) for three consecutive months

AND

ii. At least one of the following clinical circumstances:
   a. pain causing impairment of mobility or activities of daily living
   b. recurrent (>1 episode) phlebitis
   c. refractory dependent edema
   d. persistent stasis dermatitis

B. Leg ulcerations due, in the opinion of the treating physician, to venous insufficiency, that are refractory to conservative management

C. Bleeding from a varix

2. Reimbursable treatments for varicose veins of the lower extremities include the following:

A. Sclerotherapy (CPT 36470, 36471), including ultrasound guidance microfoam sclerotherapy (CPT 36465, 36466) for up to three sclerotherapy treatment sessions per leg

B. Ambulatory phlebectomy (37765, 37766)

C. Ligation and excision (37700, 37718, 37722, 37735, 37760, 37780, 37785)

D. Radiofrequency ablation (RFA) (36475, 36476)

E. Endovenous laser therapy (EVLT) (36478, 36479)

F. Subfascial endoscopic perforator surgery (SEPS) (37500)
3. Treatment of asymptomatic varicose veins (ICD-9 454.9; ICD-10 I83.90-I83.93) or spider veins/telangiectasia (ICD-9 448.9; ICD-10 I78.8, I78.9 CPT 36468) is NOT reimbursable as this is deemed cosmetic and thus not medically necessary.

4. The following varicose vein interventions are NOT reimbursable, as they are deemed experimental, investigational or unproven because there is not yet a sufficient body of peer-reviewed literature supporting their efficacy:

   A. Transilluminated powered phlebectomy (TIPP, Trivex™)
   B. Transdermal laser therapy
   C. Intense pulsed-light source (photothermal sclerosis)
   D. Endomechanical ablative approaches using rotating catheter (e.g., ClariVein™ Catheter) (e.g., mechanical occlusion chemically assisted ablation [MOCA], mechanic-chemical endovenous ablation [MCEA], mechanically enhanced endovenous chemical ablation [MEECA]) (CPT 36473, 36474)
   E. Endovascular embolization with cyanoacrylate adhesive (e.g., VenaSeal™ Closure System)( CPT 36482, 36483)
   F. Coil embolization
   G. Cryotherapy, including transilluminated cryotherapy.

References

Hayes, Inc. Health Technology Brief. Polidocanol Endovenous Microfoam (Varithena) 1% for Treatment of Varicose Veins. Lansdale, PA: Hayes, Inc.: May 12, 2016, Annual Review January 08, 2018

Hayes, Inc. Health Technology Brief. Endovenous Mechanochemical Ablation (MOCA) (ClariVein Occlusion Catheter, Nonthermal Vein Ablation System [Vascular Insights LLC]) for


Todd KL 3rd, Wright DI; VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam preparation 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology. 2014;29(9):608-618(Oct)


Hayes Health technology Brief- Varitehe(na) (Polidocanl Injectable foam) for Treatment of Varicose veins.Publication Date March 31,2015. Accessed at Hayesinc.com


National Institute for Clinical Excellence (UK) Interventional Procedure Guidance 37. Transilluminated powered phlebectomy for varicose veins. Issue date: Jan 2004

Drafted By/Date: B. Fisher, MD 05/30/07
Approved By/Date: QM Committee 07/31/07
Revised By/Date: B. Fisher, MD 05/24/09
Approved By/Date: QM Committee 07/28/09
Revised By/Date: M. McNeil, MD 08/20/13
Approved By/Date: QM Committee 09/10/13
Revised By/Date: M. McNeil, MD 01/27/16
Approved By/Date: QM Committee 02/16/16
Revised By/Date: M. McNeil, MD 01/29/18
Approved By/Date: QM Committee 02/20/18

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.